USPH VS CLDX Stock Comparison

Performance

USPH
100/100

USPH returned 2.89% in the last 12 months. Based on SPY's performance of -13.44%, its performance is above average giving it a score of 100 of 100.

CLDX
10/100

CLDX returned -25.40% in the last 12 months. Based on SPY's performance of 9.73%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

USPH
61/100

7 analysts offer 12-month price targets for USPH. Together, they have an average target of 0, the most optimistic target put USPH at 0 within 12-months and the most pessimistic has USPH at 0.

CLDX
68/100

7 analysts offer 12-month price targets for CLDX. Together, they have an average target of 45, the most optimistic target put CLDX at 63 within 12-months and the most pessimistic has CLDX at 27.

Sentiment

USPH
67/100

USPH had a bullish sentiment score of 66.64% across Twitter and StockTwits over the last 12 months. It had an average of 2.88 posts, 0.12 comments, and 0.00 likes per day.

CLDX
66/100

CLDX had a bullish sentiment score of 66.43% across Twitter and StockTwits over the last 12 months. It had an average of 4.73 posts, 1.31 comments, and 2.10 likes per day.

Technicals

USPH
50/100

USPH receives a 50 of 100 based on 14 indicators. 6 are bullish, 6 are bearish.

CLDX
64/100

CLDX receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.

Earnings

USPH
69/100

USPH has missed earnings 2 times in the last 20 quarters.

CLDX
10/100

CLDX has missed earnings 8 times in the last 20 quarters.

Profit

USPH
61/100

Out of the last 20 quarters, USPH has had 20 profitable quarters and has increased their profits year over year on 5 of them.

CLDX
10/100

Out of the last 20 quarters, CLDX has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

USPH
55/100

USPH has had a higher than average amount of volatility over the last 12 months giving it a score of 54 of 100.

CLDX
45/100

CLDX has had a lower than average amount of volatility over the last 12 months giving it a score of 45 of 100.

Dividend

USPH
19/100

USPH's most recent dividend was $0.82 per share, based on a share price of $87.22. It was a payout ratio of 95.21% compared to their total earnings.

CLDX

"Dividend" not found for CLDX

All score calculations are broken down here to help you make more informed investing decisions

US Physical Therapy Inc Summary

New York Stock Exchange / USPH

Healthcare

Medical - Care Facilities

U.S. Physical Therapy, Inc., through its subsidiaries, operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. It operates through two segments, Physical Therapy Operations and Industrial Injury Prevention Services. The company offers industrial injury prevention services, including onsite injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments through physical therapists and specialized certified athletic trainers for Fortune 500 companies, and other clients comprising insurers and their contractors. As of December 31, 2021, it operated 591 clinics in 39 states; and managed 35 physical therapy practice facilities. The company was founded in 1990 and is based in Houston, Texas.

Celldex Therapeutics, Inc Summary

Nasdaq / CLDX

Healthcare

Biotechnology

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Power up your portfolio